In this respect, it has also been reported a direct contribution of p53 in sensitivity to EGFR TKIs in NSCLC and that changes in p53 status affected primary sensitivity as well as acquired resistance to EGFR-TKIs according to cell type. This evidence concerns the gene TP53 and non-small cell lung carcinoma.